Neogen (NASDAQ:NEOG) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Neogen (NASDAQ:NEOG) announced its earnings results on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03, FiscalAI reports. The firm had revenue of $224.69 million during the quarter, compared to analyst estimates of $208.50 million. Neogen had a positive return on equity of 2.23% and a negative net margin of 117.61%.The business’s revenue was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $0.11 EPS.

Neogen Stock Performance

Shares of NEOG stock opened at $7.38 on Thursday. The company has a market capitalization of $1.60 billion, a P/E ratio of -1.54 and a beta of 1.96. Neogen has a fifty-two week low of $3.87 and a fifty-two week high of $13.15. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.26 and a current ratio of 3.58. The stock has a 50 day moving average price of $6.52 and a two-hundred day moving average price of $5.83.

Institutional Investors Weigh In On Neogen

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC increased its position in Neogen by 217.0% during the 1st quarter. AQR Capital Management LLC now owns 52,410 shares of the company’s stock valued at $443,000 after purchasing an additional 35,878 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Neogen by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 129,813 shares of the company’s stock valued at $1,125,000 after purchasing an additional 5,638 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Neogen by 5,687.3% during the first quarter. Jones Financial Companies Lllp now owns 33,393 shares of the company’s stock valued at $290,000 after buying an additional 32,816 shares during the period. Goldman Sachs Group Inc. raised its stake in Neogen by 14.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,678,493 shares of the company’s stock worth $14,553,000 after buying an additional 209,990 shares in the last quarter. Finally, United Services Automobile Association purchased a new stake in Neogen in the first quarter worth about $112,000. 96.73% of the stock is currently owned by institutional investors.

Key Stories Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Q2 results beat: Neogen reported $0.10 EPS vs. $0.08 consensus and revenue of $224.69M vs. $208.5M expected — a clear quarter-over-expectations beat that supports near-term revenue momentum. Press Release
• Positive Sentiment: FY26 revenue guidance raised: Management issued revenue guidance of $845.0M–$855.0M vs. consensus ~$824.5M, signaling organic growth or contribution from recent initiatives/segments that should help FY26 top-line expectations. (EPS guidance was not provided in the summary.)
• Neutral Sentiment: Investor / analyst interest ahead of the print: Multiple previews and analyst note roundups (Benzinga, Seeking Alpha) circulated before the release, keeping the stock in focus but reflecting no consensus upgrade/downgrade trend. Earnings Preview
• Neutral Sentiment: Brokerage stance is mixed-to-cautious: Coverage shows an average “Hold” recommendation, suggesting analysts are waiting for clearer margin recovery or sustained revenue acceleration before turning bullish. Brokerage Summary
• Neutral Sentiment: Company materials: Management posted a press release and slide deck for the quarter (useful for investors who want segment-level and guide detail). Slide Deck
• Negative Sentiment: Profitability concerns persist: Neogen reported a negative net margin (~-117.6%) and still has a negative P/E, which keeps investors focused on whether revenue growth will translate into consistent operating profitability. These metrics likely cap upside despite the guidance beat.
• Negative Sentiment: Market reaction tempered: With mixed signals (beat + raised revenue guide vs. poor margins and a neutral broker view), investors appear to be selling into the news rather than rewarding the print — explaining today’s downward price move.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NEOG shares. Piper Sandler set a $6.50 price target on shares of Neogen and gave the company a “neutral” rating in a research note on Thursday, October 16th. CJS Securities raised shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neogen in a report on Monday, December 29th. Finally, Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.83.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.